According to Zacks, “Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in patients with solid tumors. Aptose Biosciences Inc., formerly known as Lorus Therapeutics Inc., is headquartered in Toronto, Canada. “
APTO has been the topic of several other reports. Roth Capital reiterated a buy rating on shares of Aptose Biosciences in a report on Thursday, May 23rd. HC Wainwright dropped their target price on Aptose Biosciences from $8.50 to $6.00 and set a buy rating on the stock in a report on Wednesday, August 7th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $5.25.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.01. On average, equities research analysts predict that Aptose Biosciences will post -0.59 EPS for the current year.
Large investors have recently made changes to their positions in the stock. Geode Capital Management LLC purchased a new stake in shares of Aptose Biosciences during the 4th quarter valued at about $33,000. Boston Advisors LLC purchased a new stake in Aptose Biosciences during the 1st quarter worth approximately $36,000. Gagnon Securities LLC purchased a new stake in Aptose Biosciences during the 2nd quarter worth approximately $146,000. Patriot Financial Group Insurance Agency LLC increased its holdings in Aptose Biosciences by 37.3% during the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 78,829 shares of the biotechnology company’s stock worth $158,000 after purchasing an additional 21,400 shares during the last quarter. Finally, Virtu Financial LLC purchased a new stake in Aptose Biosciences during the 1st quarter worth approximately $198,000. Institutional investors and hedge funds own 6.74% of the company’s stock.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Read More: Stop Order
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.